Effects of a high-glucose environment on the pituitary growth hormone-releasing hormone receptor: type 1 diabetes compared with in vitro glucotoxicity. Am J Physiol Endocrinol Metab 294: E740-E751, 2008. First published February 19, 2008 doi:10.1152/ajpendo.00141.2007.-The present study investigated the effects of diabetes and high glucose on GHRH receptor (GHRH-R) mRNA and protein levels in the pituitary of diabetic rats 2, 21, and 60 days post-streptozotocin (post-STZ) administration. Two days post-STZ, the 2.5-kb GHRH-R mRNA transcript was increased. Twenty-one days post-STZ, both the 2.5-and 4-kb transcripts and a 72-kDa 125 I-GHRH-GHRH-R complex were elevated. Sixty days post-STZ, the 4-kb transcript remained increased and the 45-kDa 125 I-GHRH-GHRH-R complex (functional receptor) was decreased. Hypothalamic GHRH mRNA and serum total IGF-I levels were reduced at all three time points. To better understand the role of high glucose on GHRH-R regulation, time-course effects of 33 compared with 6 mM D-glucose (DG) were examined in cultured anterior pituitary cells from 2-mo-old healthy rats. Membrane lipoperoxidation was present in 33 mM DG, and GHRH-R mRNA levels were diminished after 24 h, Fluo-GHRH internalization was marginal after 16 -24 h, and GHRH-induced cAMP levels were decreased after 24 and 48 h. Altogether, these results indicate that the increase of the 2.5-kb GHRH-R mRNA transcript in vivo could be a consequence of a decrease of hypothalamic GHRH mRNA levels in STZ rats. Since it does not affect primarily functional GHRH-R levels, the initial diminution of circulating IGF-I levels could result from a decreased GHRH-R stimulation by GHRH. Thus, the effect of glucotoxicity would be related to a decrease of functional GHRH-R protein, as observed in rats 60 days post-STZ and in cultured pituitary cells from healthy rats exposed to a high-glucose environment.
SPECIFIC BINDING of hypothalamic growth hormone-releasing hormone (GHRH) to the anterior pituitary somatotroph GHRH receptor (GHRH-R) (1, 24, 30, 48) induces intracellular cAMP production (3), leading to GH secretion (2, 54) , synthesis (2) , and proliferation (4) . In addition to protein kinase A (10, 58) , protein kinase C (10), and mitogen-activated protein kinase (44, 59) , pathways can be activated by GHRH. GHRH-R, a member of the subfamily B-III of G protein-coupled receptors, has been cloned in the anterior pituitary of several mammalian species (14, 17, 18, 19, 26, 30, 52) . The presence of Ϸ2.5-and Ϸ4-kb GHRH-R mRNA transcripts has been reported (26, 30) in the rat and mouse pituitary. Although the short and most abundant transcript generates the functional 423-amino acid GHRH-R (30, 33) , the structure of the 4-kb transcript remains to be elucidated. Correlative evidence (15) suggests that an increased ratio of 4/2.5-kb transcript levels may reflect a shift of high-to low-affinity GHRH binding sites. Chemical crosslinking with 125 I-GHRH(1-44)NH 2 identified the presence of specific Ϸ27-and Ϸ42-kDa (16) or Ϸ28-, Ϸ47-, and Ϸ65-kDa-labeled entities in the rat pituitary (6) . The 47-kDa entity corresponds to the functional GHRH-R (30) . The lowest molecular weight entity has been proposed to represent a degradation product of the 47-kDa entity, and the highest a glycosylated or dimeric form of GHRH-R (6, 7). The presence of GHRH and GHRH-R mRNAs has also been demonstrated in extrapituitary rat tissues (29) , and the Henle's loop of the renal medulla contains the highest GHRH-R mRNA levels (5) . Pituitary and renal GHRH-R mRNA levels are regulated in a complex manner according to physiological and hormonal status (5, 15, 20, 21, 23, 32, 34, 37, 42, 51) .
Changes occurring in chronic pathologies, such as diabetes, induce disturbances of the somatotroph axis. In spontaneous diabetic rats and in the streptozotocin (STZ)-induced diabetic rat (STZ rat), a widely used model of type 1 diabetes, pulsatile GH secretion and GHRH-induced GH release are decreased (35, 38, 53, 55) , and declines of pituitary GH and hypothalamic GHRH mRNA levels are observed (8) . In addition, hypothalamic GHRH content rises 2-4 days post-STZ administration, returns to normal after 7 days, and declines thereafter (25) . In these rats, pituitary GH content, serum GH, and insulin-like growth factor I (IGF-I) levels decreased over time (25) . Other studies have shown a greater in vivo (11) or in vitro (49) sensitivity of GHRH to induce GH secretion in STZ rats. These discrepancies may originate from variations in the duration and severity of diabetes as well as STZ dosage and route of administration.
Studies in STZ rats have provided important information in identifying specific dysfunctions of the GHRH-GH-IGF-I axis. However, the time course of changes in both GHRH-R mRNA and protein levels has not yet been investigated. Therefore, the aims of the present study were to assess the dynamics of these changes in the anterior pituitary of 2-mo-old male rats 2, 21, and 60 days post-STZ administration and to determine whether or not glucotoxicity exerts direct effects on GHRH-R levels and functionality using cultured anterior pituitary cells from 2-mo-old healthy male rats.
MATERIALS AND METHODS
Animal handling and STZ administration. Two-mo-old male Sprague Dawley rats (Charles River Canada, St. Constant, QC, Canada; Tables 1 and 2 ) were kept in temperature-(22°C), humidity-(65%), and lighting-controlled (12:12-h light-dark cycle, lights on at 0700) rooms. They had free access to standard rat chow (2018-Teklad Global, 18% protein rodent diet) and water. They were either housed individually in metabolic cages for the duration of the short-term studies (2 and 21 days) or maintained in metabolic cages for the first 2 wk of the long-term study (60 days) and 1 day/wk subsequently. The rats were randomly assigned to either control or diabetic groups. Body weight (BW), food and water intakes, and urine volume were assessed before STZ administration to ensure that both groups were identical.
Diabetes was induced by a single intraperitoneal injection of STZ (Sigma-Aldrich Canada, Oakville, ON, Canada) freshly solubilized in 0.5 ml of citrate buffer, pH 4.5 (Sigma-Aldrich Canada) (8) . A dosage of 100 and 65 mg STZ/kg BW was administered for the short-and long-term studies, respectively, in agreement with the protocol of Busiguina et al. (8) . They were chosen to allow the correlation of our results with the published data and because serum glucose levels can be normalized in these conditions, upon insulin treatment. This intraperitoneal dose range has also been shown to cause no general anterior pituitary or renal toxicity (8, 12) , whereas intravenous administration of 100 -200 mg/kg BW STZ results in a GH secretory defect (27) . Control rats were injected with 0.5 ml of citrate buffer. In the short-term studies, BW, food and water intakes, and urine volume were recorded every day. In the long-term study, they were assessed every 3 days of the first 2 wk and once/wk thereafter. Urine glucose and ketones were analyzed on 24-h samples with Chemstrip 10 (Roche Diagnostics, Laval, QC, Canada). Diabetes was defined by the appearance of glucosuria (Ն1,000 mg/dl) and polyuria (Ϸ70 ml/24 h) within 24 or 24 -72 h in the short-and long-term studies, respectively.
Tissue handling. The rats were killed by rapid decapitation 2, 21, or 60 days post-STZ administration or citrate buffer alone, in a block design fashion, between 0830 and 1130. Trunk blood was collected and blood glucose analyzed with a Glucometer Elite (Bayer Diagnostics, Toronto, ON, Canada), and tissues were rapidly dissected out. Macroscopic evaluation of the anterior pituitaries from STZ rats revealed an Ϸ50% reduction in size 21 and 60 days post-STZ administration compared with controls. For Northern blotting, anterior pituitaries and livers were snap-frozen in liquid nitrogen and stored at Ϫ80°C until RNA extraction (Table 1) . For cross-linking, anterior pituitaries were rinsed and homogenized as previously described (Table 2 ) (6, 7). For cell culture, anterior pituitaries from 2-mo-old healthy male Sprague Dawley rats were cut into four to six pieces and rinsed in 25 mM HEPES collecting buffer (57) . The protocol was approved by the Animal Care Committee of the Centre Hospitalier de l'Université de Montréal Research Center, in compliance with guidelines of the Canadian Council on Animal Care.
Isolation and culture of anterior pituitary cells. Cells were isolated by enzymatic digestion (57) , centrifuged (800 g, 4 min, 4°C), and washed three times in DMEM supplemented with 6 mM D-glucose (DG), 10% fetal bovine serum, 1% penicillin [50 U/ml streptomycin (1.25 g/ml); Invitrogen Canada, Burlington, ON, Canada], and 0.1% amphotericin (Sigma-Aldrich Canada). They were cultured for 16 h in this medium and subsequently for 1, 4, 24, or 48 h in new medium containing 6 or 33 mM D-or L-glucose (37°C, 95% air-5% CO2; Ϸ1 ϫ 10 6 cells/ml). The culture media were changed after 24 h. The experimental concentrations of glucose did not vary significantly over time (10 Ϯ 2), as determined by the hexokinase assay (Sigma-Aldrich Canada). In some internalization experiments, cells were cultured for 4 h in 6 mM DG and 16 h in the medium containing 6 or 33 mM D-or L-glucose and detached by gentle manual scraping. They were centrifuged (800 g, 5 min, 4°C), washed 3 times in cold Tris-acetate buffer containing 50 mM sucrose, and suspended in the same buffer at a concentration of 0.5-0.8 ϫ 10 6 cells/ml (57) . Cell viability, assessed by the trypan blue exclusion method, was Ն91% after harvesting.
Detection of apoptosis and necrosis in cultured anterior pituitary cells. Cells were plated on sterile glass coverslips in multiwell dishes at a density of Ϸ1 ϫ 10 6 cells/ml culture medium, containing 6 mM DG, and cultured for 16 h. They were subsequently incubated for 4, 24, or 48 h in new medium containing 6 or 33 mM DG followed by a 20-min incubation at 4°C with 100 l of YO-PRO-1 or propidium iodide solution to label apoptotic and necrotic cells, respectively (Vybrant Apoptosis Assay Kit No. 4; Molecular Probes, Eugene, OR). Cells were kept on ice in the dark for immediate fluorescence microscopy analysis with a Nikon Eclipse TE600 microscope (ϫ20 objective) equipped with a Coolsnap camera (ϫ0.45), a Nikon super high-pressure mercury lamp, and filters for excitation/emission of green (485/520 nm), red (595/660 nm), and blue fluorescence (360/ 460 nm) (Nikon Canada, Montreal, QC, Canada). Fluorescence microscopy image acquisition was performed on Ϸ240 individual cells from four independent experiments for each condition. Data were analyzed with MetaMorph 4.6 software (Universal Imaging; Canberra-Packard Canada, Mississauga, ON, Canada). The results were expressed as percentages, compared with the total number of cells, assessed in each condition by phase contrast microscopy.
Detection of membrane lipoperoxidation in cultured anterior pituitary cells. Cells were plated as described above and cultured in 6 mM DG for 16 h. They were subsequently incubated for 1, 4, 24, or 48 h in medium containing 6 or 33 mM DG and then in medium containing 1 M 4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora3a,4a-diaza-S-indacene-3-undecanoic acid (C11-BODIPY 581/591; Molecular Probes) in a final concentration of 0.5% vol/vol DMSO for 30 min at 37°C (41) . Incubations were also performed in medium containing 6 or 33 mM DG and 2.5 mM of the antioxidant Trolox (water-soluble analog of vitamin E) or 0.5 mM of the prooxidant cumene hydroperoxide (CHP) to determine the minimal and maximal level of oxidation in the cells. After being washed twice in cold PBS, the cells were mounted on glass slides and kept on ice in the dark for immediate fluorescence microscopy analysis. Ratios of green (presence of lipoperoxidation)/red fluorescence (absence of lipoperoxidation) (40) were determined by fluorescence imaging. The intra-assay coefficient of variation was Յ15% in all experiments. The results were expressed as percentages of the relative ratio of fluorescence intensities/cell.
Analysis of GHRH-R mRNA transcript levels in the anterior pituitary by Northern blotting. Total RNA was extracted from the anterior pituitary of control and STZ rats with TRIzol (Invitrogen Canada). Northern blotting was performed on 12 g of total RNA samples, as described previously (5), with minor modifications {overnight hybridization at 65°C in fresh Robbins solution with 10 ϫ 10 6 counts ⅐ min [ 32 P]RPR64 Ϫ1 ⅐ ml Ϫ1 , membranes washed in standard saline citrate (SSC), pH 7.0 (2ϫ SSC/0.1% SDS, 23°C, 2 ϫ 10 min; 1ϫ SSC-0.1% SDS, 65°C, 1-2 ϫ 10 min; 0.5ϫ SSC-0.1% SDS, 65°C, 1-2 ϫ 10 min)}. Stripped membranes were rehybridized with rat GAPDH and 28S rRNA probes (American Type Culture Collection, Rockville, MD). Amounts of GHRH-R mRNA were normalized in each lane with GAPDH, after assessment of the stability of GAPDH mRNA compared with 28S rRNA, in our experimental conditions. Specificity of the [ 32 P]RPR64 cDNA probe and linearity of the reaction were verified in each experiment's (5) GHRH-R mRNA transcripts, and GAPDH mRNA and 28S rRNA levels were quantified by densitometry using an IS1000 digital imaging system (Alpha InfoTech, Montreal, QC, Canada). The intra-assay coefficient of variation of normalized GHRH-R mRNA signals was Յ10% in all experiments. The results were expressed as percentages of relative densities to those of control groups, using a fixed amount of total RNA as well as total RNA from each anterior pituitary.
Analysis of GHRH mRNA levels in the hypothalamus by real-time RT-PCR. Total RNA from the hypothalamus of control and STZ rats was extracted with TRIzol and resuspended in nuclease-free water (Ambion, Austin, TX). Quality control of RNA samples was assessed in a 2100 Bioanalyzer using the RNA 6000 Nano LabChip kit (Agilent Technologies, Mississauga, ON, Canada). The RNA integrity number of all samples was Ͼ9.0. Reverse transcription (RT) of 2 g total RNA was performed with the SuperScript II RT kit and oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers according to the manufacturer's protocol (Invitrogen Canada), including RNase H treatment. Rat GHRH and GAPDH (internal control) mRNA levels were determined by realtime PCR in separate tubes at 1:50 (GHRH) and 1:100 (GAPDH) dilution of the RT product and reagents from the Quantitect SYBR Green PCR kit. Reactions were performed in triplicate (final volume 25 l), in the presence of 300 nM sense and antisense primers, in a Rotor Gene 3000 real-time thermal cycler (Montreal Biotech, Montreal, QC, Canada). No template and no amplification controls were included in each experiment to confirm the specificity of the reactions. The parameters included a single cycle at 95°C for 15 min followed by 45 cycles at 94°C for 15 s, annealing at 58°C for 30 s, extension at 72°C for 30 s, and a melting step from 72 to 99°C (ramping at 1°C/s). Specificity of the PCR products [GHRH forward: 5Ј-CATG-CAGACGCCATCTTCAC-3Ј; GHRH reverse: 5Ј-AACCTGGAT-CTTTGTTCCTG G-3Ј (nt 286-410, Genbank NM_031577); GAPDH forward: 5Ј-AGGGCTGCCTTCTCTTGTGAC-3Ј; GAPDH reverse: 5Ј-TGGGTAGAATCATACTGGAACATGTAG-3Ј (nt 82-182, Genbank M17701)] was established by melting curve analysis and elec- trophoresis on 2% agarose gel containing 0.5 g/ml of ethidium bromide, with a 100-bp molecular weight standard (Invitrogen Canada). The results were analyzed with the Rotor-Gene application software. A five-point standard curve was performed for each gene tested, using 1:5 serial dilutions (1:5 to 1:3,125) of hypothalamus total RNA from 2-mo-old healthy male rats. Hypothalamic GHRH mRNA relative levels were obtained in STZ rats by comparing with those of control rats, according to the Pfaffl (43) equation and using GAPDH as reference gene. The intra-assay coefficient of variation of GHRH and GAPDH cycle threshold (C T) values was Յ2.5% in all experiments.
Analysis of GHRH-R mRNA levels in cultured anterior pituitary cells by real-time RT-PCR.
Total RNA was extracted with TRIzol, and the samples were resuspended in nuclease-free water. Quality control of the RNA samples was assessed as above. The RNA integrity number of all samples was Ն9.8. RT of 2 g total RNA and real-time PCR were also performed as in Analysis of GHRH mRNA levels in the hypothalamus by real-time RT-PCR, except that annealing was at 52°C for 30 s. Specificity of the PCR products [GHRH-R forward: 5Ј-CTGCTGTCTTCCAGGGTGAT-3Ј; GHRH-R reverse: 5Ј-TAG-GAGATGTGGAGGCCAAC-3Ј (nt 578-736, Genbank NM_012850); GAPDH forward: 5Ј-GGGTGTGAACCACGAGAAAT-3Ј; GAPDH reverse: 5Ј-ACTGTGGTCATGAGCCCT TC-3Ј (nt 1242-1376, Genbank NM_017008)] was determined also as in Analysis of GHRH mRNA levels in the hypothalamus by real-time RT-PCR. A standard curve was performed for each gene tested using anterior pituitary total RNA from 2-mo-old male rats. Quantification of GHRH-R mRNA relative levels in cells cultured with 33 mM DG compared with those of cells cultured with 6 mM DG was performed as above. The intra-assay coefficient of variation of GHRH-R and GAPDH C T values was Յ2.5% in all experiments.
Analysis of GHRH-GHRH-R cross-linked complexes. [ 125 I-Tyr 10 ] human (h)GHRH(1-44)NH2 (
125 I-GHRH, 2,000 Ci/mmol; Amersham Biosciences, Baie d'Urfé, QC, Canada) binding was carried out at equilibrium (23°C, 60 min) on rat anterior pituitary homogenates from STZ and control rats (250 l, Ϸ375 g of protein) in 50 mM Tris-acetate (pH 7.4) containing 5 mM MgCl2, 5 mM EDTA, 1 mM diprotin, 100 M leupeptin (Sigma-Aldrich Canada), 0.42% BSA, and Ϸ175 pM 125 I-GHRH in a final volume of 1.5 ml (6, 7). Some experiments were performed to compare cross-linking patterns with 100 and 500 pM 125 I-GHRH in anterior pituitaries from 2-mo-old healthy rats. Nonspecific binding was determined in the presence of 1 M rat (r)GHRH (1-29)NH2 (synthesized in our laboratory) (13) . Incubation was stopped by centrifugation (12,000 g, 5 min, 4°C), and the pellets were resuspended in 25 mM HEPES (pH 8.0) containing 5 mM of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (Sigma-Aldrich Canada) (6, 7). Incubation (23°C, 30 min) was stopped in 50 mM glycine (7, 8) . The final pellets were solubilized in 75 l of Laemmli buffer (22) and processed for SDS-12% PAGE, blotting, and autoradiography (6, 7). Precision Plus protein standards (Bio-Rad) were run in each gel.
125 I-GHRH-GHRH-R complex was quantified using an IS1000 digital imaging system. The intra-assay coefficient of variation was Յ10% in all experiments. The results were expressed in percentage of specific densities (specific binding: total Ϫ nonspecific) relative to those of controls, using a fixed amount of protein.
Deglycosylation of GHRH-GHRH-R cross-linked complexes.
125 I-GHRH-GHRH-R complex was deglycosylated using a glycoprotein deglycosylation kit (Calbiochem, San Diego, CA) containing Nglycosidase F, endo-␣-N-acetylgalactosaminidase, ␣2-3,6,8,9-neuraminidase, ␤1,4-galactosidase, and ␤-N-acetylglucosaminidase according to the manufacturer's protocol. Pellets with 200 g of protein from rat anterior pituitary homogenates, resuspended in 30 l picopure water, were used. In each experiment, as a negative control the tissue preparation was submitted to the deglycosylation protocol without enzymes. A standard of glycosylated proteins (phosphorylase B, BSA, aldolase, triose phosphate isomerase, trypsin inhibitor, lysozyme; all supplied with the kit) was used as positive control and detected with Ponceau red. The reactions were stopped on ice by acetone precipitation and centrifugation (12, (57) . Cells cultured in petri dishes were cytocentrifuged onto glass slides, and coverslips were apposed for microscopic visualization (57) , and those cultured on glass coverslips in multiwell dishes were mounted onto glass slides. Slides were kept on ice in the dark for immediate fluorescence microscopy analysis. Total fluorescence was quantified using the pseudo color/segmented histogram function of MetaMorph, and the results were expressed in intensity units (57) .
Determination of immunoreactive cAMP levels in cultured anterior pituitary cells. Anterior pituitary cells were cultured in multiwell plates (Ϸ1.2 ϫ 10 5 cells ⅐ well Ϫ1 ⅐ 150 l Ϫ1 ) in 6 mM DG for 16 h and subsequently for 4, 24, or 48 h in new medium containing 6 or 33 mM DG. At the end of the culture period, the cells were washed twice with DMEM-0.2% BSA and equilibrated 30 min with this medium before a 10-min stimulation (37°C) with rGHRH(1-29)NH 2 (0.1-100 nM) and 1 mM 3-isobutyl-1-methylxanthine (Sigma-Aldrich Canada). Basal levels were determined in DMEM-0.2% BSA-1 mM 3-isobutyl-1-methylxanthine alone, which was used for GHRH serial dilutions. Forskolin (10 M, Ͻ0.01% vol/vol DMSO; Sigma-Aldrich Canada) was the positive control in each experiment. Reactions were stopped by adding the lysis buffer supplied with the enzyme immunoassay kit. Total cAMP was measured using the nonacetylation procedure of the cAMP Direct Biotrak enzyme immunoassay kit (Amersham Biosciences). Optical densities were measured at 450 nm in a Bio-Rad model 3550 microplate reader. The intra-assay coefficient of variation was Յ10% in all experiments. Total basal and GHRH-stimulated levels of immunoreactive cAMP were expressed in picomoles per well (36) . Net GHRH-induced cAMP levels (minus basal cAMP levels) were expressed as percentages of relative levels compared with those obtained in the presence of 10 nM rGHRH for each culture period.
Serum IGF-I immunoassay. Total IGF-I serum levels were determined with a commercial RIA kit (R&D Systems, Minneapolis, MN). All samples from each group were analyzed in duplicate in a single assay. The intra-assay coefficient of variation was 5.6%, and the lower sensitivity limit was 3.5 pg/ml.
Statistical analysis. The results were expressed as means Ϯ SE. Data from experimental (diabetes, deglycosylation, radioligand, and glucose concentrations) and control conditions were compared by unpaired Student's t-test, with Welch correction, when variances were significantly different. Changes in the level of lipoperoxidation over time in cells cultured with 33 mM DG as well as the combined effects of glucose concentration and Trolox or CHP on cell membrane lipoperoxidation were analyzed by ANOVA, followed by Dunnett's multiple comparison test. exhibited ketoneuria (40 mg/dl); however, at 21 and 60 days post-STZ, urinary ketone levels exceeded 60 mg/dl in all diabetic rats (data not shown). At 2, 21, and 60 days post-STZ, the BW of diabetic rats was decreased to 85-89 (P Ͻ 0.01 to P Ͻ 0.001), 67-70 (P Ͻ 0.001), and 60 -73% (P Ͻ 0.001), respectively, of age-matched controls, and their right kidney wet weight/100 g BW was increased to 119 -121, 132-151, and 170 -171% (P Ͻ 0.01 to P Ͻ 0.001), respectively, of age-matched controls. Food intake per 24 h was unchanged at 2 days post-STZ but increased to 157-184% (P Ͻ 0.001) by 21 and 60 days postdiabetes induction compared with agematched controls. Water intake and urine volume/24 h increased three to six times (P Ͻ 0.001) and to seven to 20 (P Ͻ 0.001) times, respectively, by 2-60 days post-STZ. No deaths occurred over the 2-to 60-day experimentation periods.
GHRH mRNA levels in the hypothalamus of STZ rats. As shown in Fig. 1 , hypothalamic GHRH mRNA levels decreased to 60, 49, and 67% of age-matched controls (P Ͻ 0.05 to P Ͻ 0.01) by 2, 21, and 60 days post-STZ, respectively.
GHRH-R mRNA transcript levels in the anterior pituitary of STZ rats. GHRH-R mRNA levels were analyzed by Northern blotting, allowing the quantification of 2.5-and 4-kb transcripts. Both were present in the gland of control and diabetic rats 2, 21, and 60 days post-STZ, as reported previously in healthy young rats (15, 30) . Levels of GHRH-R mRNA transcripts showed several changes according to the length and severity of diabetes (Fig. 2) . When expressed per 12 g total RNA, 2.5-kb GHRH-R mRNA transcript levels were increased to 140 and 150% of age-matched controls by 2 (Fig. 2, A and B) and 21 (Fig. 2, A and C) days post-STZ, respectively (P Ͻ 0.05). They returned to control levels by 60 days post-STZ (Fig. 2, A and D) , indicating a decrease compared with shorter periods of diabetes. A significant increase of 4-kb transcript levels was observed at 21 and 60 days post-STZ compared with age-matched controls [280 (P Ͻ 0.001) and 170% (P Ͻ 0.05), respectively; Fig. 2, A, C, and D] . Combined levels of 2.5-and 4-kb transcripts were increased to 150 and 180% (P Ͻ 0.01) by 2 and 21 days post-STZ and returned to normal by 60 days postdiabetes induction (P Ͻ 0.01). Finally, the 4/2.5-kb ratio of transcripts was not modified by 2 days post-STZ but increased to 220 (P Ͻ 0.001) and 170% (P Ͻ 0.05) at 21 and 60 days post-STZ, respectively. Anterior pituitary total RNA content did not change by 2 days post-STZ but decreased to 40 -43% of controls (P Ͻ 0.001) at 21 and 60 days postdiabetes, confirming our visual observation of a diminished anterior pituitary size at these time points. Therefore, when GHRH-R mRNA levels were expressed as a function of total RNA content per anterior pituitary, differences were seen mainly at the 2.5-kb GHRH-R mRNA transcript levels, which decreased to 63 and 52% (P Ͻ 0.05) at 21 and 60 days post-STZ, respectively, compared with age-matched controls (data not shown).
I-GHRH-GHRH-R complex levels in the anterior pituitary of STZ rats.
The presence of 72 Ϯ 2-, 45 Ϯ 1-, and 24 Ϯ 1-kDa 125 I-GHRH-labeled complexes was observed in the gland of both control and diabetic rats. Specific binding, determined in the presence of 1 M rGHRH(1-29)NH 2 , represented 60 -75% of total binding for the 72-and 45-kDa entities and 40 -55% of total binding for the 24-kDa entity. The level of complexes showed a number of changes during the evolution of diabetes (Fig. 3, A-D) . The density of the 72-kDa complex increased to 260% (P Ͻ 0.05) by 21 days post-STZ (Fig. 3C ). This increase did not remain significant (160%) at 60 days post-STZ (Fig. 3D ) compared with age-matched controls. The density of the 45-kDa complex decreased to 45% of that in age-matched controls (P Ͻ 0.05) by 60 days post-STZ (Fig. 3,  A and D) . The level of the 24-kDa complex did not change in the course of diabetes. A low level of specific Ϸ150-kDa complex (3-7% of total densities) was also detected, but it did not change with diabetes. When complex levels were expressed as a function of total protein content per anterior pituitary, differences were seen mainly at the level of the 45-kDa complex. A decrease to 40 -45% of age-matched control levels was observed at 21 and 60 days post-STZ (P Ͻ 0.05; data not shown).
Serum IGF-I levels in STZ rats. Immunoreactive IGF-I levels declined to 71, 24, and 63% of age-matched controls 2 [STZ: 1,004 Ϯ 99 ng/ml; controls: 1,410 Ϯ 95 ng/ml (P Ͻ 0.05)], 21 [STZ: 539 Ϯ 54 ng/ml; controls: 2,231 Ϯ 135 (P Ͻ 0.001)], and 60 days [STZ: 1,339 Ϯ 139 ng/ml; controls: 2,098 Ϯ 146 (P Ͻ 0.01)] post-STZ, respectively.
Deglycosylated 125 I-GHRH-GHRH-R complex levels in the anterior pituitary of normal rats. Using a panel of enzymes,
including N-glycosidase F, endo-␣-N-acetylgalactosaminidase, and ␣2-3,6,8,9-neuraminidase, deglycosylation experiments in tissue preparations from 2-mo-old healthy rats showed that the low abundance of 153 Ϯ 5-kDa 125 I-GHRH-GHRH-R-specific complexes was reduced to 105 Ϯ 5 kDa (P Ͻ 0.05; Fig. 4) . No other change was seen in the profile of 125 I-GHRH-GHRH-R cross-linked complexes in our experimental conditions, even when optimal enzyme concentrations were increased by twofold.
Effect of radioligand concentration on the density of 125 
I-GHRH-GHRH-R complexes in the anterior pituitary of normal rats.
Our preliminary data in baby hamster kidney cells, stably transfected with human or rat GHRH-R, revealed significant increases of Ϸ100 and Ϸ150-kDa-specific 125 I-GHRH-GHRH-R complexes when 500 pM 125 I-GHRH was used instead of 100 pM in cross-linking experiments (56) . This approach was taken to induce changes of rat anterior pituitary 125 I-GHRH-GHRH-R complexes, compatible with receptor dimerization/oligomer- Fig. 1 . Growth hormone-releasing hormone (GHRH) mRNA levels in the hypothalamus of diabetic and control rats at 2, 21, and 60 days poststreptozotocin (post-STZ) administration; 1:150 (GHRH) and 1:300 (GAPDH) dilutions each of reverse transcription (RT) reactions were analyzed by real-time PCR. GHRH mRNA levels were normalized with GAPDH. GHRH mRNA levels in diabetic rats were expressed in %relative density compared with that of age-matched controls established at 100%. Results represent the mean Ϯ SE of 1 experiment performed in triplicate using 6, 6, and 7 STZ rats and 6, 6, and 5 controls at 2, 21, and 60 days post-STZ, respectively. *P Ͻ 0.05; **P Ͻ 0.01 compared with respective control levels.
ization. Cross-linking experiments, performed with 100 or 500 pM 125 I-GHRH, revealed changes in the relative intensity of 25-and 69-kDa-specific complexes compared with the 48-kDa complex (Fig. 5, A and B) . A decrease in the intensity of the 25 Ϯ 1-kDa band to 63% (P Ͻ 0.02) and an increase in the density of the 69 Ϯ 2-kDa band to 160% (P Ͻ 0.01) were observed without any significant change in the level of other molecular weight entities, suggesting a dimerization of the functional GHRH-R with a truncated form.
Effect of glucose concentration on apoptosis, necrosis, and membrane lipoperoxidation in cultured anterior pituitary cells from normal rats.
The percentages of fluorescent apoptotic cells after a 16-to 24-h culture period were 13 Ϯ 1 and 9 Ϯ 4% with 6 and 33 mM DG, respectively, whereas those of necrotic cells were 12 Ϯ 1 and 10 Ϯ 1%, respectively. The percentages of fluorescent apoptotic cells, after a 48-h culture period, were 5 Ϯ 3 and 6 Ϯ 1% with 6 and 33 mM DG, respectively, and that of necrotic cells was 6 Ϯ 1% with both glucose concen- Fig. 2 . GHRH receptor (GHRH-R) mRNA transcript levels in the anterior pituitary of diabetic (Dia) and control (C) rats at 2, 21, and 60 days post-STZ administration. Samples of 12 g total RNA from each rat pituitary were analyzed by Northern blotting. A: autoradiographic representation of GHRH-R mRNA transcripts and GAPDH mRNA levels from a representative Dia and C rat at 2, 21, and 60 days post-STZ administration. B, C, and D: Dia GHRH-R mRNA normalized levels were expressed as %relative density compared with the age-matched control group established at 100%. Results represent the mean Ϯ SE of 1 experiment performed once, using 8 STZ and 8 C rats. GHRH-R mRNA levels were normalized with GAPDH. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.001 compared with respective control levels. I-GHRH-labeled complexes were expressed as %relative density compared with the age-matched C group established at 100%. Results represent the mean Ϯ SE of 3 independent experiments performed in duplicate, using 2 C and 3 STZ rats per experiment. *P Ͻ 0.05 compared with respective control levels.
trations. No significant variations occurred at any time when the cells were cultured in either 6 or 33 mM DG. The dynamics of anterior pituitary cell membrane lipoperoxidation were examined after a 1-, 4-, 24-, and 48-h culture in 6 or 33 mM DG. As shown in Fig. 6 , A and C, top, the ratio of fluorescence intensity per cell was maximal after 1 h. It increased to 380% in cells cultured in 33 mM DG compared with those cultured in 6 mM (P Ͻ 0.001). This level of lipoperoxidation was not different from that seen in cells exposed to 33 mM DG for 24 h in the presence of 0.5 mM CHP [Fig. 6, B and C, bottom (d) ]. It remained elevated to 250, 180, and 240%, when cells were exposed to 33 mM DG for 4, 24, and 48 h (P Ͻ 0.01), respectively (Fig. 6, A and C, top) . The lipoperoxidation level was lower at 24 (P Ͻ 0.001) and 48 h (P Ͻ 0.01) compared with 1 and 4 h. Lipoperoxidation was prevented in anterior pituitary cells cultured in 33 mM DG for 24 h, when 2.5 mM Trolox was present [ Fig. 6, B and C, bottom (b) ].
Effect of glucose concentration on GHRH-R mRNA levels in cultured anterior pituitary cells from normal rats. GHRH-R mRNA levels were quantified by real-time RT-PCR, allowing for high sensitivity with small amounts of cells. Normalized GHRH-R mRNA levels were not changed in cells incubated with 33 mM DG for 4 h (Fig. 7) compared with GHRH-R mRNA levels in cells incubated with 6 mM DG. They were decreased to 77 and 91% after 24-and 48-h incubation in the presence of 33 mM DG and returned to control levels after 72-h incubation (Fig. 7) .
Effect of glucose concentration on Fluo-GHRH internalization in cultured anterior pituitary cells from normal rats.
After 40-min incubation at 4°C with Fluo-GHRH, a low level of fluorescence was observed at the surface of cells incubated with 6 or 33 mM DG (Fig. 8B) . Because Fluo-GHRH internalization is time and temperature dependent, the incubation time of 90 min at 37°C was selected as optimal on the basis of our previous results in freshly dispersed anterior pituitary cells (57) . When pituitary cells are warmed at 37°C for 90 min, a punctate pattern appears with moderate to high levels of fluorescence due to internalization and concentration of Fluo-GHRH in organelles (57) . In pituitary cells cultured for 16 -24 h in the presence of 6 mM DG, these changes were correlated with an increase in total fluorescence to 160% (P Ͻ 0.001) and Fluo-GHRH internalization [ Fig. 8, A (a) and B] . In cells cultured in the presence of 33 mM DG, no significant increase of fluorescence and internalization was observed [ Fig. 8A (b) ], and the total fluorescence level was not different from that with 6 mM DG at 4°C (Fig. 8B) .
Effect of glucose concentration on GHRH-induced cAMP levels in cultured anterior pituitary cells from normal rat.
Neither basal nor forskolin-stimulated levels of immunoreactive cAMP were altered after 4-, 24-, and 48-h culture in the presence of 33 mM DG compared with those in 6 mM DG (data not shown). The rGHRH(1-29)NH 2 -induced response was not affected after a 4-h culture in the presence of 33 mM DG (Fig. 9A) . However, after 24-h culture in 33 mM DG, cAMP levels induced by 0.1, 1, 10, and 100 nM rGHRH(1-29)NH 2 decreased to 47 (P Ͻ 0.05), 63 (P Ͻ 0.05), 59 (P Ͻ 0.01), and 55% (P Ͻ 0.01), respectively (Fig. 9B) , compared with cells incubated with 6 mM DG. Similarly, after 48-h culture in 33 mM DG, cAMP levels induced by 1, 10, and 100 nM rGHRH(1-29)NH 2 declined to 67 (P Ͻ 0.05), 63 (P Ͻ 0.01), and 48% (P Ͻ 0.01) of control values, respectively (Fig. 9C) . Fig. 4 . Effect of deglycosylation on 125 I-GHRH-GHRH-R complex levels in normal rat anterior pituitary homogenates. Deglycosylation, cross-linking, and SDS-PAGE were performed as described in MATERIALS AND METHODS and Fig.  3 . Autoradiographic representation of 125 I-GHRH-labeled complexes (total binding) from 2-mo-old rat anterior pituitary after incubation in the absence (Ϫ) or presence (ϩ) of deglycosylation enzymes. Results represent the mean Ϯ SE of 2 independent experiments performed in duplicate. Fig. 5 . Effect of radioligand concentration on 125 I-GHRH-GHRH-R complex levels in normal rat anterior pituitary. Cross-linking and SDS-PAGE were performed as described in MATERIALS AND METHODS and Fig. 3 . A: densities of 125 I-GHRH-labeled complexes are expressed per 200 g of total protein as %density relative to that obtained for the 48-kDa band. B: autoradiographic representation of 125 I-GHRH-labeled complexes from 2-mo-old rat anterior pituitary. Results represent the mean Ϯ SE of 2 independent experiments performed in duplicate (interassay apparent molecular weight variation Ͻ6%). *P Ͻ 0.05; **P Ͻ 0.01 for the 69-and 25-kDa bands, respectively, when homogenates were incubated with 500 pM radioligand compared with 100 pM.
DISCUSSION
Type 1 diabetes, induced in rats by a single injection or multiple injections of STZ, has been employed in numerous studies to identify the in vivo effects of uncontrolled hyperglycemic states. Several perturbations of the GHRH-GH-IGF-I somatotroph axis have been identified in STZ rats. However, the regulation of anterior pituitary GHRH-R at both the mRNA and protein levels has not been investigated in relation to the duration and severity of diabetes and hyperglycemia. Moreover, these changes have not been compared with those obtained after the direct exposure of normal anterior pituitary cells to high glucose.
The hypothalamo-pituitary GHRH-GHRH-R system plays an important role in stimulating GH secretion and synthesis (2, 54) as well as somatotroph proliferation (4) . In the pituitary of STZ rats, GHRH-R mRNA levels were submitted to a timedependent regulation. At 2 days postdiabetes induction, a time at which no change in daily food intake was observed and a slight decrease of BW was present, hypothalamic GHRH mRNA levels were already greatly decreased. In parallel, the 2.5-kb anterior pituitary GHRH-R mRNA transcript, coding for the functional GHRH-R, was increased, but pituitary total RNA content was unchanged. Levels of the 45-kDa 125 I-GHRH-GHRH-R complex, representing the functional GHRH-R (Ϸ47 kDa in other studies) (6, 7) and that of other 125 I-GHRH-GHRH-R complexes, were also unchanged. Since hypothalamic GHRH content has been reported to increase significantly only during the early stage of diabetes (2-4 days post-STZ) (26) , enhanced GHRH tone could initially contribute to upregulate the 2.5-kb pituitary GHRH-R mRNA transcript (17) . Alternatively, since hypothalamic functions are perturbed in STZ rats (20, 47) , increased GHRH content could result from a decreased capacity of hypothalamic neurons to release the peptide, leading to compensatory upregulation of the 2.5-kb transcript. Because serum total IGF-I was already decreased, by 2-days post-STZ it may be proposed to result primarily from dampening of pituitary GHRH-R activation by GHRH.
Twenty-one days post-STZ, BW and food intakes were substantially modified and hypothalamic GHRH mRNA levels decreased, as reported previously by Busiguina et al. (8) . Under the same conditions of STZ administration, we observed that pituitary GHRH-R mRNA transcripts and the 4/2.5-kb ratio were increased, suggesting a decrease in the number of high-affinity GHRH binding sites, as reported in aged rats (15) . Although the structure of the 4-kb transcript is currently unknown, our preliminary evidence (56) suggests that it could represent a 2.5-kb GHRH-R mRNA transcript bound to an adapter protein, thus preventing optimal translation. In parallel, an increase in the 72-kDa 125 I-GHRH-GHRH-R complex level could result from an elevated level of 24/45-kDa dimer formation in such a perturbed cellular environment. In the present study, we have shown that dimerization of GHRH-R entities can occur in the anterior pituitary cells of healthy rats. In addition, recent data from McElvaine and Mayo (31) , showing a dimerization of the human GHRH-R with a COOH-terminal truncated variant, strengthen this hypothesis. Therefore, in the anterior pituitary of diabetic rats, dimerization of GHRH-R species could participate in the decreased responsiveness to GHRH, leading to a reduction of anterior pituitary size and a substantial decline of total IGF-I circulating levels.
Sixty days post-STZ, BW and food intakes remained altered, and hypothalamic GHRH mRNA levels were still reduced, but a trend toward a lower reduction than at 21 days post-STZ was observed. The pituitary 2.5-kb GHRH-R mRNA transcript was decreased and the 4-kb transcript remained elevated, resulting in an increase of the 4/2.5-kb ratio and a substantial diminution of the 45-kDa 125 I-GHRH-GHRH-R complex. Interestingly, total IGF-I circulating levels were partly restored compared with those measured at 21 days post-STZ.
Our present results in a rat model of STZ-induced diabetes and weight loss do not entirely support the hypothesis that changes in anterior pituitary GHRH-R arise exclusively from nonfasting weight loss. Rather, it suggests that GHRH-R mRNA transcripts and functional protein are regulated in a complex manner in models of STZ-diabetic rats and that hyperglycemia plays a role in addition to that of other metabolic and hormonal factors. Apart from GHRH, a number of hormonal regulators could participate in the changes of GHRH-R levels in the pituitary. Thyroid hormones and glucocorticoids have been shown to increase GHRH-R mRNA levels (23, 32, 34, 37, 42, 51) . In STZ rats, circulating levels of glucocorticoids and thyroid hormones are increased (9) and decreased (39, 46) , respectively. Since physiological levels of both are required for optimal GHRH-R expression in the pituitary (23, 32, 34, 37, 42, 51) , changes in their circulating levels with diabetes could contribute to some of the alterations observed in GHRH-R mRNA levels. However, the dynamics of changes in the concentration of these serum hormones will have to be correlated with binding proteins and nuclear receptors to clearly establish a causal role in pituitary GHRH-R dysregulation. Increased IGF-I (50) and insulin levels (28) have been shown to negatively regulate pituitary GHRH-R mRNA, and a diminution of their circulating levels in STZ rats could also be involved. However, Kim et al. (20) have proposed that the catabolic effect of weight loss, but not insulinopenia, reduced circulating levels of IGF-I, or hyperglycemia, is the primary regulator of pituitary GHRH-R mRNA levels in STZ-induced diabetes.
To more directly study the effect of a high-glucose environment on pituitary GHRH-R and exclude the confounding Fig. 7 . GHRH-R mRNA levels in cultured anterior pituitary cells exposed to a high DG concentration for various time periods; 1:150 (GHRH-R) and 1:300 (GAPDH) dilutions of each reverse transcription reaction were analyzed by real-time PCR. GHRH-R mRNA levels were normalized with GAPDH. GHRH-R mRNA levels in 33 mM DG were expressed as %relative density compared with 6 mM DG-matched controls established at 100%. Results represent the mean Ϯ SE of 3-4 experiments performed in duplicate. *P Ͻ 0.05; **P Ͻ 0.01 compared with respective control levels. actions of regulators of the receptor (GHRH, steroid and thyroid hormones, IGF-I, insulin) present in vivo in STZ rats, studies in cultured rat anterior pituitary cells were performed. Exposure to a high glucose level did not promote the necrosis or apoptosis of anterior pituitary cells but increased oxidative stress, as measured by membrane lipoperoxidation. In these conditions, GHRH-R mRNA levels were decreased particularly after 24-h culture, Fluo-GHRH internalization was drastically reduced, and GHRH-induced cAMP production was diminished, indicating lowered levels of functional GHRH-R as seen in diabetic rats 60 days post-STZ. This could be related in part to a transient modification of GHRH-R mRNA levels and concurrent changes in functional receptor levels due to dimerization and/or other structural alterations occurring in a glucotoxic/prooxidant environment. These in vitro results are consistent with those of Renier and Serri (45) showing that GHRH-induced GH release was decreased after exposure of cultured normal rat anterior pituitary cells to high glucose (22 mM, 72 h).
Our study is the first report to show a direct effect of high glucose on GHRH-R, indicating that it can contribute to a regulation of GHRH-R expression and functionality and contribute to decrease GHRH sensitivity in somatotrophs, leading to a decline of GH secretion in vitro (45) and in vivo (35, 38, 53, 55) . These results may reconcile some of the divergent reports on in vivo and in vitro somatotroph sensitivity to GHRH from a large variety of single time point evaluations, ranging from 2-to 60-day post-STZ administration and exclusively analyzing GHRH-R mRNA but not functional protein levels. The molecular and cellular events by which glucotoxicity-induced oxidative stress affects pituitary GHRH-R will now deserve investigation. Interestingly, in primary-cultured rabbit proximal tubule cells, the angiotensin type 1 receptor, another member of the G protein-coupled receptor family, is downregulated (mRNA and protein levels) by high glucose (25 mM) via a PKC-oxidative stress-transforming growth factor-␤1 signaling cascade (41) . A similar mechanism could be involved in GHRH-R regulation, affecting mRNA levels first and transiently. Alternatively, oxidative stress could damage GHRH-R protein structure and concurrently regulate GHRH-R mRNA levels. Therefore, this in vitro model should help to identify the mechanisms by which high glucose affects GHRH-R and develop strategies to counteract glucotoxicity.
In summary, when in vivo and in vitro data are analyzed together, it might be proposed that increase of the 2.5-kb pituitary GHRH-R mRNA transcript, seen 2 and 21 days post-STZ, could be related to the decrease of hypothalamic GHRH mRNA levels, leading to a reduced GHRH secretion. However, since it does not affect primarily functional GHRH-R levels, the initial diminution of circulating IGF-I could be considered, at least in part, as the result of a decreased GHRH-R stimulation by hypothalamic GHRH. Thus, the effect of glucotoxicity in somatotrophs would be related to a decrease of functional GHRH-R protein, such as that observed in diabetic rats 60 days post-STZ and in cultured anterior pituitary cells from healthy rats exposed to a high-glucose environment.
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